Lysodren(mitotane)
Lysodren (mitotane) is a small molecule pharmaceutical. Mitotane was first approved as Lysodren on 1982-01-01. It is used to treat adrenocortical carcinoma and cushing syndrome in the USA. It has been approved in Europe to treat adrenal cortex neoplasms. It is known to target cholesterol side-chain cleavage enzyme, mitochondrial.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Lysodren
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mitotane
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LYSODREN | HRA Pharma | N-016885 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lysodren | New Drug Application | 2024-02-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| adrenocortical carcinoma | — | D018268 | — |
| cushing syndrome | EFO_0003099 | D003480 | E24 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 8 | 5 | — | 4 | 18 |
| Adrenocortical carcinoma | D018268 | — | — | 1 | 8 | 5 | — | 4 | 18 |
| Adrenal cortex neoplasms | D000306 | — | C74.0 | 1 | 1 | 1 | — | — | 3 |
| Recurrence | D012008 | — | — | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | 1 | — | — | — | 1 |
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | D000309 | — | — | — | — | — | — | 1 | 1 |
| Adrenal gland neoplasms | D000310 | EFO_0003850 | C74 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mitotane |
| INN | mitotane |
| Description | Mitotane is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 53-19-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1670 |
| ChEBI ID | — |
| PubChem CID | 4211 |
| DrugBank | DB00648 |
| UNII ID | 78E4J5IB5J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP11A1
CYP11A1
Organism
Homo sapiens
Gene name
CYP11A1
Gene synonyms
CYP11A
NCBI Gene ID
Protein name
cholesterol side-chain cleavage enzyme, mitochondrial
Protein synonyms
cholesterol 20-22 desmolase, Cholesterol desmolase, cholesterol monooxygenase (side-chain cleaving), CYPXIA1, Cytochrome P450 11A1, cytochrome P450 family 11 subfamily A polypeptide 1, Cytochrome P450(scc), cytochrome P450, subfamily XIA (cholesterol side chain cleavage), steroid 20-22-lyase
Uniprot ID
Mouse ortholog
Cyp11a1 (13070)
cholesterol side-chain cleavage enzyme, mitochondrial (Q9QZ82)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,251 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lysodren
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,177 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use